Literature DB >> 9131248

Protein targets of xenobiotic reactive intermediates.

N R Pumford1, N C Halmes.   

Abstract

Many xenobiotics are metabolically activated to electrophilic intermediates that form covalent adducts with proteins; the mechanism of toxicity is either intrinsic or idiosyncratic in nature. Many intrinsic toxins covalently modify cellular proteins and somehow initiate a sequence of events that leads to toxicity. Major protein adducts of several intrinsic toxins have been identified and demonstrate significant decreases in enzymatic activity. The reactivity of intermediates and subcellular localization of major targets may be important in the toxicity. Idiosyncratic toxicities are mediated through either a metabolic or immune-mediated mechanism. Xenobiotics that cause hypersensitivity/autoimmunity appear to have a limited number of protein targets, which are localized within the subcellular fraction where the electrophile is produced, are highly substituted, and are accessible to the immune system. Metabolic idiosyncratic toxins appear to have limited targets and are localized within a specific subcellular fraction. Identification of protein targets has given us insights into mechanisms of xenobiotic toxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131248     DOI: 10.1146/annurev.pharmtox.37.1.91

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  22 in total

Review 1.  Drug Adverse Reaction Target Database (DART) : proteins related to adverse drug reactions.

Authors:  Zhi Liang Ji; Lian Yi Han; Chun Wei Yap; Li Zhi Sun; Xin Chen; Yu Zong Chen
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Evidence for cellular protein covalent binding derived from styrene metabolite.

Authors:  Wei Yuan; Hua Jin; Jou-Ku Chung; Jiang Zheng
Journal:  Chem Biol Interact       Date:  2010-05-12       Impact factor: 5.192

3.  Electrophilic adduction of ubiquitin activating enzyme E1 by N,N-diethyldithiocarbamate inhibits ubiquitin activation and is accompanied by striatal injury in the rat.

Authors:  Olga M Viquez; Samuel W Caito; W Hayes McDonald; David B Friedman; William M Valentine
Journal:  Chem Res Toxicol       Date:  2012-08-22       Impact factor: 3.739

Review 4.  An overview on the proposed mechanisms of antithyroid drugs-induced liver injury.

Authors:  Reza Heidari; Hossein Niknahad; Akram Jamshidzadeh; Mohammad Ali Eghbal; Narges Abdoli
Journal:  Adv Pharm Bull       Date:  2015-03-05

5.  Loss of autophagy promotes murine acetaminophen hepatotoxicity.

Authors:  Yuki Igusa; Shunhei Yamashina; Kousuke Izumi; Yoshihiro Inami; Hiroo Fukada; Masaaki Komatsu; Keiji Tanaka; Kenichi Ikejima; Sumio Watanabe
Journal:  J Gastroenterol       Date:  2011-11-29       Impact factor: 7.527

Review 6.  Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.

Authors:  Nicholas Moore
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

7.  Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.

Authors:  S D Lytton; U Berg; A Nemeth; M Ingelman-Sundberg
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

8.  Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury.

Authors:  Naoko Hanawa; Mie Shinohara; Behnam Saberi; William A Gaarde; Derick Han; Neil Kaplowitz
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

9.  Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo.

Authors:  Keisuke Ikehata; Tatyana G Duzhak; Nadezhda A Galeva; Tao Ji; Yakov M Koen; Robert P Hanzlik
Journal:  Chem Res Toxicol       Date:  2008-06-12       Impact factor: 3.739

Review 10.  Toxicology of autoimmune diseases.

Authors:  K Michael Pollard; Per Hultman; Dwight H Kono
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.